Q1 FY27 results: revenue Rs 822M, PAT Rs 132M; buy-back and acquisition announced

Results View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹230.00

prior close

₹238.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+1.7% vs market

Pharmaceuticals peers, median of 162sector-0.8%+1.9% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+8.3

10m

+6.8

15m

+9.5

30m

+6.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1-0.6+1.7-0.8+1.9

Next day

+0.1+0.5-0.4-0.5+0.6

+2.6+1.9+0.8+0.2+2.4

+2.6+2.3+0.3+0.1+2.5

+4.3+3.6+0.7+0.5+3.9

+3.0+4.0-0.9+0.4+2.6

+1.7+4.0-2.2+1.4+0.3

15d

+1.2+4.9-3.6+0.3+0.9

+4.9+5.9-1.0+1.6+3.3

+3.2+4.8-1.6+2.7+0.5

-6.5pendingpending-2.4-4.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 revenue from operations rose to Rs 822.32M from Rs 756.12M YoY. Net profit was Rs 131.89M versus Rs 107.95M. EPS stood at Rs 2.00. Board approved a buy-back of up to 16 lakh shares at Rs 250 each (up to Rs 400M) and acquired 85 percent in Aequitas Healthcare for Rs 208M.

Likely market impact

Buy-back and acquisition signal capital return and growth moves; results are steady with modest YoY growth.